ATRC - AtriCure guides Q4 revenue below consensus

AtriCure ([[ATRC]] +0.8%) expects Q4 revenue to decline ~6% Y/Y and ~+5% M/M to ~$57.7M vs. consensus of $58.11M. FY2020 to drop ~11% Y/Y to $206.5M vs. consensus of $206.97M, impacted by the global decline in surgical procedures as a result of the COVID-19 pandemic. “We are pleased with our fourth quarter and full-year results which reflect the resiliency and strength of our team, as well as the overarching unmet need in our core markets. COVID-19 continues to impact our revenue as procedure volumes remain below pre-pandemic levels globally, and each resurgence of the virus is a reminder of the strain on healthcare resources,” said Michael Carrel, President and Chief Executive Officer of AtriCure. The company is in a unique position of igniting multiple catalysts in 2021, including the hybrid Convergent procedure, EnCompass Clamp, Cryo Nerve Block therapy expansion, and aMAZE clinical trial data, leading to significant market expansion and

For further details see:

AtriCure guides Q4 revenue below consensus